Rosetta Genomics Completes Prevalidation Phase for First Diagnostic Product

Rosetta Genomics, Ltd. has announced that it has completed the prevalidation phase for its first diagnostic test. Using a single microRNA, the test is designed to differentiate squamous from non-squamous lung cancer with high sensitivity and specificity.

Rosetta Genomics diagnostic tests are currently undergoing validation testing at Columbia University Medical Center at its Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.

The company expects three diagnostic tests to be launched in 2008 including a test for cancer of unknown primary, lung cancer vs. mesothelioma, and the squamous vs. non-squamous lung cancer test which has recently passed the prevalidation phase.

"The results we have seen so far for our microRNA-based diagnostic tests are very encouraging," Said Amir Avniel, President and CEO of Rosetta Genomics. "Results of the prevalidation phase showed the test differentiated squamous from non-squamous lung cancer using microRNA biomarkers identified by us, with both high sensitivity and specificity. We expect the test to be available for clinical use in the first half of 08."